|
注册号: Registration number: |
ChiCTR2500110045 |
|
最近更新日期: Date of Last Refreshed on: |
2025-09-29 11:36:22 |
|
注册时间: Date of Registration: |
2025-09-29 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
脑白质胆碱能通路受损与老年抑郁症临床特点及认知功能关系的研究 |
|
Public title: |
Study on the relationship between impaired white matter cholinergic pathway and clinical features and cognitive function of elderly depression |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
脑白质胆碱能通路受损与老年抑郁症临床特点及认知功能关系的研究 |
|
Scientific title: |
Study on the relationship between impaired white matter cholinergic pathway and clinical features and cognitive function of elderly depression |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张新乔 |
研究负责人: |
张新乔 |
|
Applicant: |
Zhang Xinqiao |
Study leader: |
Zhang Xinqiao |
|
申请注册联系人电话: Applicant telephone: |
+86 136 9914 3282 |
研究负责人电话:
Study leader's |
+86 136 9914 3282 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
7581752@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
7581752@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市西城区德胜门外安康胡同5号 |
研究负责人通讯地址: |
北京市西城区德胜门外安康胡同5号 |
|
Applicant address: |
5 Ankang Hutong, Deshengmenwai, Xicheng District, Beijing, China |
Study leader's address: |
5 Ankang Hutong, Deshengmenwai, Xicheng District, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
首都医科大学附属北京安定医院 |
||
|
Applicant's institution: |
Beijing Anding Hospital Affiliated to Capital Medical University |
||
|
研究负责人所在单位: |
首都医科大学附属北京安定医院 |
||
|
Affiliation of the Leader: |
Beijing Anding Hospital Affiliated to Capital Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2023)科研第(159)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
首都医科大学附属北京安定医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Beijing Anding Hospital affiliated to Capital Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-07-27 00:00:00 | ||
|
伦理委员会联系人: |
贾京津 |
||
|
Contact Name of the ethic committee: |
Jia Jingjing |
||
|
伦理委员会联系地址: |
北京市西城区德胜门外安康胡同5号北京安定医院3号楼2层241伦理委员会办公室 |
||
|
Contact Address of the ethic committee: |
Ethics Committee Office 241, 2nd Floor, Building 3, Beijing Anding Hospital, No. 5 Ankang Hutong, Deshengmenwai, Xicheng District, Beijing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 5834 0320 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
anding_lunli@sina.com |
|
研究实施负责(组长)单位: |
北京安定医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing Anding Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市西城区德胜门外安康胡同5号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
5 Ankang Hutong, Deshengmenwai, Xicheng District, Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
北京市属医院科研培育计划 |
||||||||||||||||||||||
|
Source(s) of funding: |
Beijing Municipal Hospital Scientific Cultivation Program |
||||||||||||||||||||||
|
研究疾病: |
老年期抑郁障碍 |
||||||||||||||||||||||
|
Target disease: |
Late life depression |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
1.老年抑郁患者认知损害的模式 2.脑白质胆碱能通路受损与老年患者的抑郁症状特点及认知功能的三者之间的关系。 |
||||||||||||||||||||||
|
Objectives of Study: |
1.Pattern of cognitive impairment in elderly depressed patients 2.The relationship between impaired white matter cholinergic pathway and depressive symptoms and cognitive function in elderly patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1. 伴影响神经心理检查疾病,如听力、视力严重障碍,失语,优势侧偏瘫等; 2. 未使用可能影响认知的药物; 3. 并发严重心、肝、肾等重要器官功能衰竭; 4. 既往有脑血管事件发生; 5. 孤立关键部位的大面积梗死,阿尔茨海默病、帕金森病、额颞叶痴呆或亨廷顿病等神经系统变性病引起的认知功能障碍; 6. 其他病因导致的认知功能障碍,如中枢神经系统创伤、肿瘤、感染、代谢性疾病,正常压力脑积水,叶酸、维生素B12缺乏,甲状腺功能低下等; 7. 排除其他脑白质疾病; 8. 癫痫或特殊药物服用史或酒精或药物依赖; 9. 无心脏起搏器、神经刺激器、人工金属心脏瓣膜、体内顺磁性金属异物、严重幽闭恐怖症、重度高热等MRI禁忌症; 10. 近三个月未进行过电休克治疗。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Presence of conditions that interfere with neuropsychological assessment, such as severe hearing or visual impairment, aphasia, or dominant-side hemiplegia; 2. No use of medications that may affect cognitive function; 3. No concurrent severe failure of vital organs, including heart, liver, or kidney; 4. No history of prior cerebrovascular events; 5. No cognitive impairment due to large infarcts in critical isolated regions, or neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, or Huntington’s disease; 6. No cognitive impairment due to other causes, including traumatic brain injury, tumors, infections, metabolic disorders, normal pressure hydrocephalus, folate or vitamin B₁₂ deficiency, or hypothyroidism; 7. Exclusion of other white matter diseases; 8. No history of epilepsy, use of special medications, or alcohol/drug dependence; 9. No contraindications to MRI, including cardiac pacemakers, neural stimulators, artificial metallic heart valves, intracorporeal ferromagnetic foreign bodies, severe claustrophobia, or marked hyperthermia; 10. No electroconvulsive therapy (ECT) within the past three months. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-01-01 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-04-18 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后6个月内,分享到数据平台ResMan(http://www.medresman.org.cn/) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The data should be shared on the data platform ResMan (http://www.medresman.org.cn/) within 6 months after the study completion |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用纸版病历记录表,数据采用双录入的方式,保证数据的质量及准确性,对数据库中出现的遗漏或错误的数据,将以数据质疑表的形式发给研究者,由研究者做出解释后进行修改。所有研究数据库的数据做到能够可原始记录可查。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
A paper-based medical record form is adopted for data collection, and a double-data entry method is employed to ensure data quality and accuracy. In cases of missing or erroneous data identified in the database, a data query form will be issued to the investigator. The investigator will provide explanations before any modifications are made. All data in the study database must be traceable to the original records. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |